XNASGH
Market cap4.52bUSD
Jan 08, Last price
36.59USD
1D
1.22%
1Q
77.54%
IPO
25.31%
Name
Guardant Health Inc
Chart & Performance
P/E
—
P/S
8.02
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
29.79%
Rev. gr., 5y
44.14%
Revenues
564m
+25.45%
Net income
-479m
L-26.76%
CFO
-325m
L+5.01%
Earnings
Feb 20, 2025
Profile
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 563,948 25.45% | 449,538 20.31% | ||||||
Cost of revenue | 1,045,273 | 993,916 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (481,325) | (544,378) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 685 | 1,139 | ||||||
Tax Rate | ||||||||
NOPAT | (482,010) | (545,517) | ||||||
Net income | (479,449) -26.76% | (654,588) 70.12% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 503,270 | 4,063 | ||||||
BB yield | -16.61% | -0.15% | ||||||
| Debt | ||||||||
Debt current | 27,950 | 21,878 | ||||||
Long-term debt | 1,511,662 | 1,557,421 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 96,006 | 9,179 | ||||||
Net debt | 370,828 | 567,768 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (324,975) | (309,463) | ||||||
CAPEX | (20,486) | (77,461) | ||||||
Cash from investing activities | 840,250 | 149,816 | ||||||
Cash from financing activities | 477,375 | (189,093) | ||||||
FCF | (434,285) | (582,555) | ||||||
| Balance | ||||||||
Cash | 1,168,634 | 1,011,231 | ||||||
Long term investments | 150 | 300 | ||||||
Excess cash | 1,140,587 | 989,054 | ||||||
Stockholders' equity | (2,145,536) | (1,681,934) | ||||||
Invested Capital | 3,753,990 | 3,120,577 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 111,988 | 102,178 | ||||||
Price | 27.05 -0.55% | 27.20 -72.81% | ||||||
Market cap | 3,029,275 9.00% | 2,779,242 -72.57% | ||||||
EV | 3,400,103 | 3,347,010 | ||||||
EBITDA | (438,444) | (508,416) | ||||||
EV/EBITDA | ||||||||
Interest | 2,578 | 2,577 | ||||||
Interest/NOPBT | ||||||||